• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc.

    8/12/25 6:30:10 AM ET
    $RPID
    $TRIN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Finance: Consumer Services
    Finance
    Get the next $RPID alert in real time by email
    • $20 million drawn down at closing, with access to up to an additional $25 million
    • Strengthens Company's financial position and reinforces ability to achieve positive cash flow

    LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company" or "Rapid Micro"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it has entered into a five-year, $45 million term loan facility with Trinity Capital Inc. (NASDAQ:TRIN) ("Trinity Capital").

    Proceeds from this facility will be used for general corporate purposes, which may include supporting the continued global commercial expansion of the Growth Direct system, and ongoing investments in manufacturing efficiencies, service productivity, and product cost reduction initiatives.

    "This facility significantly strengthens our financial position and supports our continued focus on long-term revenue growth, margin expansion and increasing shareholder value," said Robert Spignesi, President and CEO of Rapid Micro Biosystems. "We are pleased with the highly favorable terms of this facility, which positions us well to build on our meaningful progress across the business."

    The loan facility consists of four tranches, with the first tranche of $20 million drawn upon closing of the agreement. The second and third tranches totaling $20 million are available to be drawn subject to the achievement of certain commercial and operational milestones, and the fourth tranche of $5 million is available at the lender's discretion. Interest is payable on the outstanding principal amount at a floating rate, initially 11.5% per annum. The loan facility has a five-year term with an interest-only period of 36 months, which is extendable if future tranches are drawn down. The loan facility contains customary representations, warranties, covenants and events of default but does not require the Company to maintain a specified level of revenues or cash resources.

    The Growth Direct system is the only fully automated, non-destructive growth-based platform for MQC testing that offers manufacturers faster time to results, improved data integrity and enhanced accuracy.

    Armentum Partners acted as the Company's exclusive financial advisor on this transaction.

    To learn more about the Company and the Growth Direct® platform, please visit our website at Rapid Micro Biosystems.

    About Rapid Micro Biosystems 

    Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control ("MQC") testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

    Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company's newly-announced term loan facility, including the planned use of proceeds therefor and the intended benefits thereof.

    In some cases, you can identify forward-looking statements by terminology such as "outlook," "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to, the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company's ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; the Company's ability to achieve its goal of attaining positive cashflow; and the other important factors outlined under the caption "Risk Factors" in the Company's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on May 9, 2025, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.



    Rapid Micro Biosystems Investor Contact: 
    Michael Beaulieu, CFA 
    Vice President, Investor Relations and Corporate Communications 
    [email protected]
    
    Rapid Micro Biosystems Media Contact: 
    [email protected]

    Primary Logo

    Get the next $RPID alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RPID
    $TRIN

    CompanyDatePrice TargetRatingAnalyst
    Rapid Micro Biosystems Inc.
    $RPID
    7/28/2025$8.00Buy
    Lake Street
    Trinity Capital Inc.
    $TRIN
    5/13/2025$16.00Buy
    B. Riley Securities
    Rapid Micro Biosystems Inc.
    $RPID
    2/12/2025$8.00Overweight
    KeyBanc Capital Markets
    Trinity Capital Inc.
    $TRIN
    12/2/2024$13.00Equal Weight → Underweight
    Wells Fargo
    Trinity Capital Inc.
    $TRIN
    8/22/2023$15.50Neutral → Buy
    Compass Point
    Trinity Capital Inc.
    $TRIN
    8/7/2023$15.00Underperform → Mkt Perform
    Keefe Bruyette
    Trinity Capital Inc.
    $TRIN
    7/5/2023$15.00Buy
    Jefferies
    Trinity Capital Inc.
    $TRIN
    3/13/2023$13.50 → $11.00Mkt Perform → Underperform
    Keefe Bruyette
    More analyst ratings

    $RPID
    $TRIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Rapid Micro Biosystems with a new price target

    Lake Street initiated coverage of Rapid Micro Biosystems with a rating of Buy and set a new price target of $8.00

    7/28/25 8:29:57 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    B. Riley Securities resumed coverage on Trinity Capital with a new price target

    B. Riley Securities resumed coverage of Trinity Capital with a rating of Buy and set a new price target of $16.00

    5/13/25 10:05:49 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    KeyBanc Capital Markets initiated coverage on Rapid Micro Biosystems with a new price target

    KeyBanc Capital Markets initiated coverage of Rapid Micro Biosystems with a rating of Overweight and set a new price target of $8.00

    2/12/25 7:09:40 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    $TRIN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Estes Ronald E. bought $16,080 worth of shares (1,000 units at $16.08), increasing direct ownership by 3% to 36,779 units (SEC Form 4)

    4 - Trinity Capital Inc. (0001786108) (Issuer)

    9/15/25 4:28:42 PM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Director Estes Ronald E. bought $48,290 worth of shares (3,000 units at $16.10), increasing direct ownership by 9% to 35,779 units (SEC Form 4)

    4 - Trinity Capital Inc. (0001786108) (Issuer)

    9/12/25 4:52:46 PM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Director Estes Ronald E. bought $16,145 worth of shares (1,000 units at $16.15), increasing direct ownership by 3% to 32,779 units (SEC Form 4)

    4 - Trinity Capital Inc. (0001786108) (Issuer)

    9/4/25 4:11:54 PM ET
    $TRIN
    Finance: Consumer Services
    Finance

    $RPID
    $TRIN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Trinity Capital Inc. Provides $45 Million in Growth Capital to Rapid Micro Biosystems, Modernizing Healthcare Industry Practices

    PHOENIX, Sept. 22, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $45 million in growth capital to Rapid Micro Biosystems (NASDAQ:RPID) ("Rapid Micro"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products. Rapid Micro specializes in automating microbial quality control in mission-critical applications such as environmental monitoring, water testing, ste

    9/22/25 8:00:00 AM ET
    $RPID
    $TRIN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Finance: Consumer Services
    Finance

    AZ-VC II Launches to Fill The Funding Gap For Non-Coastal Startups; Eschews Sky-High Coastal Valuations

    Non-Coastal Venture Capital Firm AZ-VC Adds Second Vintage Vehicle to itsSuccessful $115 First Fund PHOENIX, Sept. 19, 2025 /PRNewswire/ -- AZ-VC, a U.S. venture capital firm fueling innovation outside traditional coastal markets, today announced the launch of its second fund, AZ-VC II, managing an undisclosed amount in an effort to foster innovation and momentum outside of traditional U.S. tech hubs.  The firm began its franchise in 2022, anchored by Pinnacle West Corporation (PNW: NYSE), in addition to mostly Arizona-based limited partners, including Western Alliance Bancorp (NYSE:WAL), Trinity Capital (NASDAQ:TRIN), and Salt River Project.  AZ-VC is led by Managing Partner, Jack Selby, a

    9/19/25 8:00:00 AM ET
    $PNW
    $TRIN
    $WAL
    Electric Utilities: Central
    Utilities
    Finance: Consumer Services
    Finance

    Trinity Capital Inc. Provides $100 Million in Growth Capital to Angel, Expanding its Global Impact in Values-Driven Entertainment

    PHOENIX, Sept. 18, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $100 million in growth capital to Angel Studios, Inc. (NYSE:ANGX) ("Angel Studios" or "Angel"), an unprecedented media and technology company championing values-based stories. Angel's new model empowers audiences as virtual co-producers. The more than 1.5 million Angel Guild members worldwide decide what films and television shows get made, selecting stories that amplify light and timeless values. Angel's films and s

    9/18/25 8:00:00 AM ET
    $ANGX
    $TRIN
    Movies/Entertainment
    Consumer Discretionary
    Finance: Consumer Services
    Finance

    $RPID
    $TRIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Brown Steve Louis covered exercise/tax liability with 15,731 shares, decreasing direct ownership by 2% to 813,966 units (SEC Form 4)

    4 - Trinity Capital Inc. (0001786108) (Issuer)

    9/18/25 6:26:13 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    GC, CCO, and Secretary Stanton Sarah covered exercise/tax liability with 2,537 shares, decreasing direct ownership by 2% to 140,806 units (SEC Form 4)

    4 - Trinity Capital Inc. (0001786108) (Issuer)

    9/18/25 6:22:16 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Chief Credit Officer Kundich Ronald covered exercise/tax liability with 4,037 shares, decreasing direct ownership by 2% to 213,146 units (SEC Form 4)

    4 - Trinity Capital Inc. (0001786108) (Issuer)

    9/18/25 6:20:55 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    $RPID
    $TRIN
    SEC Filings

    View All

    Trinity Capital Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Trinity Capital Inc. (0001786108) (Filer)

    8/29/25 6:51:46 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    SEC Form 10-Q filed by Rapid Micro Biosystems Inc.

    10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

    8/12/25 5:15:39 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

    8/12/25 6:33:39 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    $TRIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    2/14/24 10:04:40 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    1/22/24 5:28:26 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    2/14/23 4:17:23 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    $TRIN
    Leadership Updates

    Live Leadership Updates

    View All

    Trinity Capital Inc. Expands Equipment Finance Presence to Europe with the Appointment of Brian Geraghty as Managing Director

    PHOENIX, Sept. 2, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) (the "Company"), a leading alternative asset manager, today announced the appointment of Brian Geraghty as Managing Director of Equipment Finance, based in Dublin, Ireland. Mr. Geraghty, with over fifteen years of experience originating loans to high-growth companies, will help drive the growth of the Company's Equipment Finance business in Europe through his deep industry knowledge and established relationships. "We are pleased to welcome Brian to our team," said Ryan Little, Senior Managing Director of

    9/2/25 8:00:00 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Trinity Capital Inc. Expands Tech Lending Vertical with Appointment of Josh Mackey as Director

    PHOENIX, Aug. 25, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) (the "Company"), a leading alternative asset manager, today announced the appointment of Josh Mackey, Director of Tech Lending, based in San Francisco, California. With over a decade of experience supporting innovative technology companies across the U.S., Mr. Mackey is a trusted partner within the venture ecosystem. "It is a pleasure to welcome Josh to the Trinity team," said Phil Gager, Senior Managing Director of Tech Lending at Trinity Capital. "We believe Josh's deep industry experience will further

    8/25/25 8:00:00 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors

    LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company" or "Rapid Micro"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Dr. Dafni Bika to the Company's Board of Directors (the "Board"). "We are extremely pleased to welcome Dr. Bika to our Board of Directors," said Robert Spignesi, President and Chief Executive Officer. "Dafni has more than 25 years of leadership experience in pharmaceutical development and manufacturing science and technology. She brings a wealth of knowledge an

    5/27/25 9:00:22 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    $TRIN
    Financials

    Live finance-specific insights

    View All

    Trinity Capital Inc. Declares Cash Dividend of $0.51 per Share for the Third Quarter of 2025

    23rd Consecutive Quarter of a Consistent Dividend PHOENIX, Sept. 17, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) ("Trinity Capital" or "the Company"), a leading alternative asset manager, today announced that its Board of Directors declared a cash dividend of $0.51 per share with respect to the quarter ending September 30, 2025. This is an equivalent dividend compared to the second quarter of 2025 and marks the 23rd consecutive quarter of a consistent or increased dividend for Trinity shareholders. Summary of Third Quarter 2025 Dividend: Declaration Date September

    9/17/25 5:05:00 PM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results

    Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. Reports second quarter gross margin of 4%, representing a seven-percentage point improvement compared to the second quarter of 2024. Enters into five-year, $45 million term loan facility with $20 million funded at close. Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology c

    8/12/25 6:31:30 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Trinity Capital Inc. Reports Second Quarter 2025 Financial Results

    Total Investment Income grows 27.3% year-over-year Net Asset Value reaches new high of $923.6 million Return on Average Equity increases to 15.9% PHOENIX, Aug. 6, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) ("Trinity Capital" or "the Company"), a leading alternative asset manager, today announced its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Total investment income of $69.5 million, an increase of 27.3% year-over-yearNet investment income ("NII") of $34.8 million, or $0.53 per basic share. NII grew 30.3% year over

    8/6/25 8:05:00 AM ET
    $TRIN
    Finance: Consumer Services
    Finance